CD274 and neoplasm: Since Toplian and his colleagues first revealed that tumour PD-L1 expression reflects an immune-active microenvironment [70], several clinical trials have demonstrated that clinical responses to PD-1 blockade are correlated with PD-L1 expression in many cancer types [71,72,73,74].